<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00966693</url>
  </required_header>
  <id_info>
    <org_study_id>2009-0179</org_study_id>
    <secondary_id>NCI-2018-01857</secondary_id>
    <secondary_id>2009-0179</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT00966693</nct_id>
  </id_info>
  <brief_title>Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>Phase I/II Study of Lenalidomide (Revlimid), Thalidomide, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the best dose and side effects of lenalidomide and thalidomide,
      and how well they work with dexamethasone in treating participants with multiple myeloma that
      has come back or does not respond to treatment. Drugs used in chemotherapy, such as
      lenalidomide, thalidomide and dexamethasone, work in different ways to stop the growth of
      tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them
      from spreading.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the maximum tolerated dose (MTD) of the combination of lenalidomide and
      thalidomide and dexamethasone (LTD) in patients with relapsed/refractory multiple myeloma
      (RRMM). (Phase 1) II. To determine the overall (complete remission [CR)]+ very good partial
      response [VGPR]+ partial response [PR)] response rate of the combination after 4 cycles of
      therapy. (Phase 2)

      SECONDARY OBJECTIVES:

      I. To determine the overall response rate (ORR). (Phase 1) II. To determine the time to
      progression (TTP). (Phase 1) III. To determine the progression free survival (PFS). (Phase 1)
      IV. To determine the time to best response. (Phase 1) V. To determine the CR, VGPR. (Phase 2)
      VI. To determine the time to progression (TTP). (Phase 2) VII. To determine the progression
      free survival (PFS). (Phase 2) VIII. To determine the time to best response. (Phase 2) IX. To
      assess the safety of the combination of LTD in patients with RRMM. (Phase 2) X. Time to next
      therapy. (Phase 2) XI. Symptom measurement - multiple-symptom assessment tool. (Phase 2)

      OUTLINE: This is a dose-escalation study of lenalidomide and thalidomide.

      Participants receive lenalidomide orally (PO) on days 1-21 and thalidomide PO once daily (QD)
      on days 1-28. Participants also receive dexamethasone PO QD on days 1-4, 9-12, and 17-20 of
      courses 1-2, and days 1, 8, 15, and 22 of subsequent courses. Treatment repeats every 28 days
      for up to 8 courses in the absence of disease progression or unacceptable toxicity.

      MAINTENANCE THERAPY: Participants who have stable or responding disease to treatment receive
      lenalidomide PO on days 1-21 and thalidomide PO QD on days 1-28. Courses repeat every 28 days
      in the absence of disease progression or unacceptable toxicity. Participants may receive
      dexamethasone at the discretion of the investigator.

      After completion of study treatment, patients are followed up at 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 25, 2009</start_date>
  <completion_date type="Actual">July 20, 2018</completion_date>
  <primary_completion_date type="Actual">July 20, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete response and very good partial response</measure>
    <time_frame>Up to 9 years</time_frame>
    <description>Logistic regression will be utilized to assess the effect of patient prognostic factors on the response rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Up to 9 years</time_frame>
    <description>Logistic regression will be utilized to assess the effect of patient prognostic factors on the response rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Up to 9 years</time_frame>
    <description>Will be estimated using the method of Kaplan and Meier. Comparison of time-to-event endpoints by important subgroups will be made using the log-rank test. Cox proportional hazard regression will be employed for multivariate analysis on time-to-event outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Up to 9 years</time_frame>
    <description>Will be estimated using the method of Kaplan and Meier. Comparison of time-to-event endpoints by important subgroups will be made using the log-rank test. Cox proportional hazard regression will be employed for multivariate analysis on time-to-event outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to best response</measure>
    <time_frame>Up to 9 years</time_frame>
    <description>Will be estimated using the method of Kaplan and Meier. Comparison of time-to-event endpoints by important subgroups will be made using the log-rank test. Cox proportional hazard regression will be employed for multivariate analysis on time-to-event outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 9 years</time_frame>
    <description>Logistic regression will be utilized to assess the effect of patient prognostic factors on the toxicity rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next therapy</measure>
    <time_frame>Up to 9 years</time_frame>
    <description>Will be estimated using the method of Kaplan and Meier. Comparison of time-to-event endpoints by important subgroups will be made using the log-rank test. Cox proportional hazard regression will be employed for multivariate analysis on time-to-event outcomes.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Recurrent Plasma Cell Myeloma</condition>
  <condition>Refractory Plasma Cell Myeloma</condition>
  <arm_group>
    <arm_group_label>Treatment (lenalidomide, thalidomide, dexamethasone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive lenalidomide PO on days 1-21 and thalidomide PO QD on days 1-28. Participants also receive dexamethasone PO QD on days 1-4, 9-12, and 17-20 of courses 1-2, and days 1, 8, 15, and 22 of subsequent courses. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
MAINTENANCE THERAPY: Participants who have stable or responding disease to treatment receive lenalidomide PO on days 1-21 and thalidomide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Participants may receive dexamethasone at the discretion of the investigator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (lenalidomide, thalidomide, dexamethasone)</arm_group_label>
    <other_name>Aacidexam</other_name>
    <other_name>Adexone</other_name>
    <other_name>Aknichthol Dexa</other_name>
    <other_name>Alba-Dex</other_name>
    <other_name>Alin</other_name>
    <other_name>Alin Depot</other_name>
    <other_name>Alin Oftalmico</other_name>
    <other_name>Amplidermis</other_name>
    <other_name>Anemul mono</other_name>
    <other_name>Auricularum</other_name>
    <other_name>Auxiloson</other_name>
    <other_name>Baycuten</other_name>
    <other_name>Baycuten N</other_name>
    <other_name>Cortidexason</other_name>
    <other_name>Cortisumman</other_name>
    <other_name>Decacort</other_name>
    <other_name>Decadrol</other_name>
    <other_name>Decadron</other_name>
    <other_name>Decalix</other_name>
    <other_name>Decameth</other_name>
    <other_name>Decasone R.p.</other_name>
    <other_name>Dectancyl</other_name>
    <other_name>Dekacort</other_name>
    <other_name>Deltafluorene</other_name>
    <other_name>Deronil</other_name>
    <other_name>Desamethasone</other_name>
    <other_name>Desameton</other_name>
    <other_name>Dexa-Mamallet</other_name>
    <other_name>Dexa-Rhinosan</other_name>
    <other_name>Dexa-Scheroson</other_name>
    <other_name>Dexa-sine</other_name>
    <other_name>Dexacortal</other_name>
    <other_name>Dexacortin</other_name>
    <other_name>Dexafarma</other_name>
    <other_name>Dexafluorene</other_name>
    <other_name>Dexalocal</other_name>
    <other_name>Dexamecortin</other_name>
    <other_name>Dexameth</other_name>
    <other_name>Dexamethasonum</other_name>
    <other_name>Dexamonozon</other_name>
    <other_name>Dexapos</other_name>
    <other_name>Dexinoral</other_name>
    <other_name>Dexone</other_name>
    <other_name>Dinormon</other_name>
    <other_name>Fluorodelta</other_name>
    <other_name>Fortecortin</other_name>
    <other_name>Gammacorten</other_name>
    <other_name>Hexadecadrol</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Lokalison-F</other_name>
    <other_name>Loverine</other_name>
    <other_name>Methylfluorprednisolone</other_name>
    <other_name>Millicorten</other_name>
    <other_name>Mymethasone</other_name>
    <other_name>Orgadrone</other_name>
    <other_name>Spersadex</other_name>
    <other_name>Visumetazone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (lenalidomide, thalidomide, dexamethasone)</arm_group_label>
    <other_name>CC-5013</other_name>
    <other_name>CC5013</other_name>
    <other_name>CDC 501</other_name>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (lenalidomide, thalidomide, dexamethasone)</arm_group_label>
    <other_name>(+)-Thalidomide</other_name>
    <other_name>(-)-Thalidomide</other_name>
    <other_name>.alpha.-Phthalimidoglutarimide</other_name>
    <other_name>2, 6-Dioxo-3-phthalimidopiperidine</other_name>
    <other_name>Alpha-Phthalimidoglutarimide</other_name>
    <other_name>Contergan</other_name>
    <other_name>Distaval</other_name>
    <other_name>Kevadon</other_name>
    <other_name>N-(2,6-Dioxo-3-piperidyl)phthalimide</other_name>
    <other_name>N-Phthaloylglutamimide</other_name>
    <other_name>N-Phthalylglutamic Acid Imide</other_name>
    <other_name>Neurosedyn</other_name>
    <other_name>Pantosediv</other_name>
    <other_name>Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (+)-</other_name>
    <other_name>Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (-)-</other_name>
    <other_name>Sedalis</other_name>
    <other_name>Sedoval K-17</other_name>
    <other_name>Softenon</other_name>
    <other_name>Synovir</other_name>
    <other_name>Talimol</other_name>
    <other_name>Thalomid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Understand and voluntarily sign an informed consent form

          -  Relapsed/refractory multiple myeloma (MM) with measurable levels of myeloma
             paraprotein in serum (&gt;= 0.5 g/dl), urine (&gt;= 0.2 g excreted in a 24-hour collection
             sample), or abnormal free light chain (FLC) ratio

          -  Serum creatinine =&lt; 2.5 mg/dl

          -  Females of childbearing potential (FCBP)* must have a negative serum or urine
             pregnancy test with a sensitivity of at least 50 mlU/mL within 10-14 days prior to and
             again within 24 hours of starting lenalidomide and must either commit to continued
             abstinence from heterosexual intercourse or begin TWO acceptable methods of birth
             control, one highly effective method and one additional effective method AT THE SAME
             TIME, at least 28 days before she starts taking lenalidomide. FCBP must also agree to
             ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact
             with a female of childbearing potential even if they have had a successful vasectomy.
             All patients must be counseled at a minimum of every 28 days about pregnancy
             precautions and risks of fetal exposure.

               -  A female of childbearing potential is a sexually mature woman who: 1) has not
                  undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally
                  postmenopausal for at least 24 consecutive months (i.e., has had menses at any
                  time in the preceding 24 consecutive months).

          -  Absolute neutrophil count &gt; 1000 cells/mm^3

          -  Platelet count &gt; 50,000 cells/mm^3 for patients with &lt; 50% of bone marrow plasma cells
             and platelet count &gt; 25,000 cells/mm^3 for patients in whom &gt; 50% of the bone marrow
             nucleated cells were plasma cells

          -  Total bilirubin =&lt; 2.0 mg/dL

          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) &lt; 3 x
             upper limit of normal (ULN)

          -  Able to take prophylactic anticoagulation, warfarin or equivalent agent

          -  Patient is able to understand and comply with the terms and conditions of the
             lenalidomide and thalidomide counseling program

          -  All study participants must be registered into the mandatory RevAssist program, and be
             willing and able to comply with the requirements of RevAssist, AND the S.T.E.P.S.
             program

        Exclusion Criteria:

          -  Any serious medical condition, or psychiatric illness that would prevent the subject
             from signing the informed consent form

          -  Pregnant or breast feeding females. (Lactating females must agree not to breast feed
             while taking lenalidomide)

          -  Use of any cancer therapy within 21 days prior to beginning cycle 1 day 1 of therapy
             (radiation therapy allowed within 5 days of completion of radiation therapy).

          -  Known hypersensitivity to thalidomide, lenalidomide and dexamethasone.

          -  The development of erythema nodosum if characterized by a desquamating rash while
             taking thalidomide or similar drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donna Weber</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>August 26, 2009</study_first_submitted>
  <study_first_submitted_qc>August 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2009</study_first_posted>
  <last_update_submitted>November 20, 2018</last_update_submitted>
  <last_update_submitted_qc>November 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Ichthammol</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 22, 2019</submitted>
    <returned>May 17, 2019</returned>
    <submitted>October 1, 2019</submitted>
    <returned>October 24, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

